Argolyn Bioscience
Durham
About Argolyn Bioscience
Argolyn Bioscience is a biotechnology company that develops peptide drug candidates to treat serious diseases and disorders. The company’s products are based on amino acid analog substitution technology. The company's products include ABS201 for schizophrenia and ABS212 for pain.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Estimated revenue: $1K – $10K
- Total funding: $16.8M
- Funding stage: Early Stage Venture
- Last round: Series A (Jun 2007)
- Phone: (919)806-4634
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Canonical: https://fsome.com/organization/argolyn-bioscience-3218719 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.